Breaks Categories: Stock Spotlights

FridayMay 06, 2022 2:15 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study

Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other conditions,’ and the company’s joint homing peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, ‘enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic…

Continue Reading

ThursdayApr 28, 2022 2:40 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated process, Cybin is combining controllable drug-delivery systems with novel psychedelic molecules, thus creating patent-protected, commercially scalable drug candidates. “The company currently is moving three of these drug candidates forward: CYB003, CYB004 and CYB005. Cybin’s active drug programs target major depressive disorder (CYB003), alcohol use disorder (CYB003), anxiety disorders (CYB004) and neuroinflammation (CYB005),” reads a recent article. “Cybin recently announced that it commenced a…

Continue Reading

WednesdayApr 27, 2022 1:57 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Focusing on Largely Underserved Indications

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns with Silo Pharma’s mission of identifying assets to license while funding transformative research for the well-being of patients and the health care industry. Silo Pharma focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare…

Continue Reading

WednesdayApr 27, 2022 1:39 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) KWC Committed to Providing Clinically-Backed, Accessible, Affordable Treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. A recent article reads, “While making the announcement, Kevin Nicholson, the CEO of KWC and COO of Delic, noted that the introduction…

Continue Reading

FridayApr 08, 2022 1:07 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with mental health and addiction disorders with unmet needs,” the article reads. “Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment…

Continue Reading

ThursdayApr 07, 2022 2:21 pm

PsychedelicNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves,” a recent article reads. Silo Pharma is involved in a sponsored study with Maastricht University…

Continue Reading

WednesdayApr 06, 2022 2:20 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Boundaries in Research of New Products

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products, such as psychedelics and cannabis, for the market. The company understands that research is integral for the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for treating mental issues. In addition, the company is helping reframe the psychedelic conversation while being at the forefront of the ongoing psychedelics renaissance. A recent article reads, “Delic’s focus on research is moving society closer to the full adoption…

Continue Reading

TuesdayMar 29, 2022 2:29 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, partnering to advance research and more. The company has partnered with Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University (“JHU”), to lead its planned placebo-controlled study evaluating the science and efficacy of MYCO-001, its lead psilocybin-based drug…

Continue Reading

MondayMar 21, 2022 2:10 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently received its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. According to Cybin CEO Doug Drysdale, the patent adds strong protection to the company’s growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments it is making in its CYB004 program. “Under the patent, allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT; the…

Continue Reading

MondayMar 21, 2022 1:43 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Scalable Approach to Psychedelic-Based Treatments Aimed at ‘Giving People Their Best Selves Back’

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, aims to help people live better lives through the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC”). The chain operates in multiple locations, strategically located in secondary cities to improve accessibility and reach and serve the greatest number of patients. In addition, the company’s scientific backbone, DELIC Labs, is a federally authorized psilocybin and cannabis research laboratory that dedicates its efforts to improving extraction, analytical testing and chemical processes. The lab’s R&D solutions for product lines and new intellectual property (“IP”) serve as the engine…

Continue Reading